SCHEMBL16446681

SCHEMBL16446681

COc1ccc(-c2nc(C)c3c(n2)NC(=O)C3)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP2 O95551 1/20 0.50
▸ ALDH1A1 P00352 5/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ PDE4B Q07343 2/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ PDGFRA P16234 1/20 0.40
▸ YAP1 P46937 1/20 0.40
▸ KDM1A O60341 2/20 0.39
▸ PTGS1 P23219 3/20 0.39
▸ PTGS2 P35354 3/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL16446629 0.99 TDP2 (0.49) TDP2ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL16446805 0.69 PDE4B (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL16447012 0.68 ALDH1A1 (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL25082162 0.68 ABCG2 (0.58) SMN1; SMN2MEN1KMT2ALMNAMAPT
SCHEMBL5031343 0.67 RAB9A (0.57) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL18010830 0.67 TDP2 (1.00) TDP2
SCHEMBL16446820 0.67 PDE4B (0.53) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL16446133 0.66 GAA (0.51) ALDH1A1RAB9AKDM4ELMNAMAPT
SCHEMBL16446457 0.66 TRPA1 (0.42) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL16446732 0.65 NR3C1 (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 — — EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 — — US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 — — EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 — — US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP TDP2 117/4885ALDH1A1 462/4885NPC1 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback